Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Geoffrey D Barnes

Showing results (101-110 of 290) with videos related to

Pageof 29
Sort By:
Journal of Thrombosis and Thrombolysis|January 30, 2023
Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillationDeborah DeCamillo, Brian Haymart, Xiaowen Kong, et al.
The American Journal of Medicine|December 7, 2018
Periprocedural Antithrombotic Management from a Patient Perspective: A Qualitative AnalysisJennifer Acosta, Christopher Graves, Elizabeth Spranger, et al.
Thrombosis Research|May 21, 2016
Use of decision aids for shared decision making in venous thromboembolism: A systematic reviewGeoffrey D Barnes, Brett Izzo, Marisa L Conte, et al.
Arthritis Care & Research|December 20, 2016
A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe IschemiaNayef M Kazzaz, Allecia M Wilson, Ruba Kado, et al.
Implementation Science Communications|June 29, 2023
Dynamic interplay between available resources and implementation climate across phases of implementation: a qualitative study of a VA national population health toolYing-Jen Lin, Allison Ranusch, F Jacob Seagull, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|September 11, 2020
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infectionAndrea T Obi, Geoffrey D Barnes, Lena M Napolitano, et al.
The American Journal of Cardiology|November 11, 2015
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationBrian M Salata, David W Hutton, Deborah A Levine, et al.
The Annals of Pharmacotherapy|August 14, 2018
Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and DiltiazemJenna W Bartlett, Elizabeth Renner, Erin Mouland, et al.
Thrombosis and Haemostasis|January 8, 2025
Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and RivaroxabanMehrdad Zarghami, Sina Rashedi, Gregory Piazza, et al.
Journal of General Internal Medicine|October 31, 2025
Untreated Atrial Fibrillation: Public Health Threat or Data Blind Spot?Zainab Mian, Morris Fabbri, Jay Patel, et al.
Pageof 29

Showing results (101-110 of 290) with videos related to

Sort By:
Pageof 29
Journal of Thrombosis and Thrombolysis|January 30, 2023
Adverse events in low versus normal body weight patients prescribed apixaban for atrial fibrillationDeborah DeCamillo, Brian Haymart, Xiaowen Kong, et al.
The American Journal of Medicine|December 7, 2018
Periprocedural Antithrombotic Management from a Patient Perspective: A Qualitative AnalysisJennifer Acosta, Christopher Graves, Elizabeth Spranger, et al.
Thrombosis Research|May 21, 2016
Use of decision aids for shared decision making in venous thromboembolism: A systematic reviewGeoffrey D Barnes, Brett Izzo, Marisa L Conte, et al.
Arthritis Care & Research|December 20, 2016
A 37-Year-Old Man With Primary Antiphospholipid Syndrome Presenting With Respiratory Distress and Worsening Toe IschemiaNayef M Kazzaz, Allecia M Wilson, Ruba Kado, et al.
Implementation Science Communications|June 29, 2023
Dynamic interplay between available resources and implementation climate across phases of implementation: a qualitative study of a VA national population health toolYing-Jen Lin, Allison Ranusch, F Jacob Seagull, et al.
Journal of Vascular Surgery. Venous and Lymphatic Disorders|September 11, 2020
Venous thrombosis epidemiology, pathophysiology, and anticoagulant therapies and trials in severe acute respiratory syndrome coronavirus 2 infectionAndrea T Obi, Geoffrey D Barnes, Lena M Napolitano, et al.
The American Journal of Cardiology|November 11, 2015
Cost-Effectiveness of Dabigatran (150 mg Twice Daily) and Warfarin in Patients ≥ 65 Years With Nonvalvular Atrial FibrillationBrian M Salata, David W Hutton, Deborah A Levine, et al.
The Annals of Pharmacotherapy|August 14, 2018
Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and DiltiazemJenna W Bartlett, Elizabeth Renner, Erin Mouland, et al.
Thrombosis and Haemostasis|January 8, 2025
Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and RivaroxabanMehrdad Zarghami, Sina Rashedi, Gregory Piazza, et al.
Journal of General Internal Medicine|October 31, 2025
Untreated Atrial Fibrillation: Public Health Threat or Data Blind Spot?Zainab Mian, Morris Fabbri, Jay Patel, et al.
Pageof 29